We are fully committed to partnering with you to support your patients.
We completed the test and research program for affected CPAP and BiPAP devices, and testing on ventilation devices continues. Please visit this page for the latest results.
Due to the complexities of the remediation of ventilation devices, these devices will remain on a separate timeline from CPAP and BiPAP devices.
Our clinical bulletins have been created to help update physicians on recent developments as well as provide a status update on remediation efforts.
We are transforming our processes and the way we operate so we can deliver what matters most to our patients – safe and effective therapy.”
David Ferguson
David Ferguson, Business Leader, Sleep & Respiratory Care, joined Philips in March 2021. Since then, he has led the organization through the voluntary medical device recall of certain CPAP, BiPAP and Mechanical Ventilator devices. With the comprehensive test and research program for affected CPAP/BiPAP sleep therapy devices† now complete, we asked him about what’s changed since the start of the recall, what the test results mean for patients, and what to expect from Philips Respironics in the future.
† First-generation DreamStation, System One and DreamStation Go devices
You are about to visit a Philips global content page
Continue